摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-[[tert-butyl(dimethyl)silyl]oxymethyl]-1H-pyrimidine-2,4-dione

中文名称
——
中文别名
——
英文名称
5-[[tert-butyl(dimethyl)silyl]oxymethyl]-1H-pyrimidine-2,4-dione
英文别名
——
5-[[tert-butyl(dimethyl)silyl]oxymethyl]-1H-pyrimidine-2,4-dione化学式
CAS
——
化学式
C11H20N2O3Si
mdl
——
分子量
256.377
InChiKey
YNEDAMYKGPENRD-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.58
  • 重原子数:
    17.0
  • 可旋转键数:
    3.0
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.64
  • 拓扑面积:
    74.95
  • 氢给体数:
    2.0
  • 氢受体数:
    3.0

反应信息

  • 作为反应物:
    描述:
    5-[[tert-butyl(dimethyl)silyl]oxymethyl]-1H-pyrimidine-2,4-dione1,8-二氮杂双环[5.4.0]十一碳-7-烯三乙胺三苯基膦偶氮二甲酸二乙酯 作用下, 以 四氢呋喃N,N-二甲基甲酰胺甲苯 为溶剂, 反应 75.0h, 生成 5-(tert-butyldimethylsilyloxy)methyl-N3-[2-(3,5-dinitrobenzoyloxy)ethyl]-N1-tosyluracil
    参考文献:
    名称:
    一种通过尿嘧啶环转化反应合成N-β-烯氨基羰基2-恶唑烷酮的新方法
    摘要:
    在室温、无水条件下,在 3-位带有 2-羟乙基部分的N 1-磺酰尿嘧啶衍生物与 NaH 反应得到相应的带有 β-烯氨基羰基部分的 2-恶唑烷酮。这些产品是各种 β-氨基酸和N-杂环化合物的有用的多样化前体。
    DOI:
    10.1016/j.tetlet.2021.153554
  • 作为产物:
    参考文献:
    名称:
    设计和合成尿嘧啶脲衍生物作为有效和选择性的脂肪酸酰胺水解酶抑制剂†
    摘要:
    脂肪酸酰胺水解酶(FAAH)是参与内源性大麻素(尤其是anandamide)生物降解的关键酶之一。FAAH的药理学阻断作用可恢复内源性大麻素的水平,从而在治疗炎症,抑郁和多发性硬化症方面提供治疗益处。在这项研究中,设计并合成了一系列尿嘧啶脲衍生物作为FAAH抑制剂。N-己基-2,4-二氧代-3,4-二氢嘧啶-1(2 H)-羧酰胺(1a的C5位置和侧链的结构修饰)导致FAAH抑制剂具有更高的效能和选择性。结构-活性关系(SAR)研究表明,C5吸电子取代基优选具有最佳效能,但不具有选择性,而用苯基烷基基团或联苯基取代烷基链可显着提高抑制效力和对FAAH的选择性。开发了两种高效的皮摩尔FAAH抑制剂(4c,IC 50 = 0.3±0.05 nM; 4d,IC 50 = 0.8±0.1 nM)。化合物4c以快速,选择性,非竞争性和不可逆的方式抑制FAAH。这项研究提供了几种高效和选择性的FAAH抑
    DOI:
    10.1039/c7ra02237a
点击查看最新优质反应信息

文献信息

  • NOVEL HETEROCYCLIC COMPOUNDS AND USE THEREOF IN MEDICINE AND IN COSMETICS
    申请人:GALDERMA RESEARCH & DEVELOPMENT
    公开号:US20180050992A1
    公开(公告)日:2018-02-22
    The invention relates to novel heterocyclic compounds of general formula (I), as well as their pharmaceutically acceptable salts, and their enantiomers. The invention also relates to the use thereof as a medicinal product, preferably in the prevention and/or treatment of inflammatory diseases with a neurogenic component or use thereof as a cosmetic. The compounds of the present invention act as antagonists of the CGRP-R receptor.
    这项发明涉及一般式(I)的新型杂环化合物,以及它们的药用盐和对映体。该发明还涉及将其用作药物产品,优选用于预防和/或治疗具有神经源性成分的炎症性疾病,或将其用作化妆品。本发明的化合物作为CGRP-R受体的拮抗剂。
  • ACID CERAMIDASE INHIBITORS AND THEIR USE AS MEDICAMENTS
    申请人:FONDAZIONE ISTITUTO ITALIANO DI TECHNOLOGIA
    公开号:US20150111892A1
    公开(公告)日:2015-04-23
    The present invention concerns, in a first aspect, compounds of Formula I as defined herein, pharmaceutically acceptable salts thereof and pharmaceutical compositions containing such compounds. The present invention also relates to compounds of Formula I for use as acid ceramidase inhibitors, and in the treatment of cancer and other disorders in which modulation of the levels of ceramide is clinically relevant.
    本发明涉及第一方面的I式化合物,其定义如本文所述,其药用盐以及含有这种化合物的药物组合物。本发明还涉及I式化合物的用途,用作酸酶抑制剂,以及在癌症和其他需要临床相关的调节酸酶水平的疾病治疗中的用途。
  • [EN] ACID CERAMIDASE INHIBITORS AND THEIR USE AS MEDICAMENTS<br/>[FR] INHIBITEURS DE LA CÉRAMIDASE ACIDE ET LEUR UTILISATION COMME MÉDICAMENTS
    申请人:FOND ISTITUTO ITALIANO DI TECNOLOGIA
    公开号:WO2013178576A1
    公开(公告)日:2013-12-05
    The present invention concerns, in a first aspect, compounds of Formula I as defined herein, pharmaceutically acceptable salts thereof and pharmaceutical compositions containing such compounds. The present invention also relates to compounds of Formula I for use as acid ceramidase inhibitors, and in the treatment of cancer and other disorders in which modulation of the levels of ceramide is clinically relevant.
    本发明涉及第一方面的Formula I化合物,其定义如下,以及其药用盐和含有这种化合物的药物组合物。本发明还涉及Formula I化合物作为酸酶抑制剂的用途,以及在治疗癌症和其他需要临床上调节酸酶水平的疾病中的应用。
  • Acid ceramidase inhibitors and their use as medicaments
    申请人:FONDAZIONE ISTITUTO ITALIANO DI TECHNOLOGIA
    公开号:US09428465B2
    公开(公告)日:2016-08-30
    The present invention concerns, in a first aspect, compounds of Formula I as defined herein, pharmaceutically acceptable salts thereof and pharmaceutical compositions containing such compounds. The present invention also relates to compounds of Formula I for use as acid ceramidase inhibitors, and in the treatment of cancer and other disorders in which modulation of the levels of ceramide is clinically relevant.
    本发明涉及第一方面的I式化合物,其定义如下,其药学上可接受的盐以及含有这种化合物的药物组合物。本发明还涉及I式化合物的用途,作为酸性酯胺酶抑制剂,并用于治疗癌症和其他调节酯胺水平具有临床意义的疾病。
  • 2,6-DIOXO-3,6-DIHYDROPYRIMIDINE COMPOUND, AGRICULTURAL AND HORTICULTURAL BACTERICIDE, NEMATICIDE, AND MEDICAL AND VETERINARY ANTIFUNGAL AGENT
    申请人:Nippon Soda Co., Ltd.
    公开号:US20240114908A1
    公开(公告)日:2024-04-11
    An object of the present invention is to provide a 2,6-dioxo-3,6-dihydropyrimidine compound that has excellent bactericidal and antimicrobial activity, has excellent safety, and can be industrially favorably synthesized, and an agricultural and horticultural fungicide, a nematicide, and an antifungal agent for use in medicine/animals that contain the compound as an active ingredient.
查看更多